Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.58 |
| ▸ | JAK2 | O60674 | 2/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | AXL | P30530 | 2/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.49 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | FER | P16591 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | MARK3 | P27448 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182234 | 0.86 | PDPK1 (0.58) | PDPK1JAK2GSK3BAXLDYRK1A | |
| SCHEMBL28661400 | 0.82 | PDPK1 (0.58) | PDPK1JAK2GSK3BAXLDYRK1A | |
| SCHEMBL17113571 | 0.82 | PDPK1 (0.62) | PDPK1JAK2GSK3BAXLDYRK1A | |
| SCHEMBL27983814 | 0.82 | PDPK1 (0.58) | PDPK1JAK2GSK3BAXLDYRK1A | |
| SCHEMBL11970617 | 0.81 | PDPK1 (0.53) | PDPK1JAK2GSK3BAXLDYRK1A | |
| SCHEMBL31426093 | 0.81 | PDPK1 (0.53) | PDPK1JAK2GSK3BAXLDYRK1A | |
| SCHEMBL130781 | 0.80 | ITK (0.47) | PDE3BPDE3ARXFP1 | |
| SCHEMBL10189221 | 0.80 | KIF11 (0.47) | GSK3BIDO1PRMT5WDR77ALDH1A1 | |
| SCHEMBL16095565 | 0.79 | AXL (0.50) | PDPK1JAK2GSK3BAXLAURKB | |
| SCHEMBL5677771 | 0.79 | MAP2K4 (0.51) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1422849-A | indazole derivatives | PFIZER (US) | 2003-06-11 | — | — | CN | claimed |
| US-12630516-B2 | Compounds | NRG THERAPEUTICS LTD. (GB) | 2026-05-19 | — | — | US | disclosed |
| EP-4208442-B1 | MPTP INHIBITORS | NRG THERAPEUTICS LTD (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| EP-4486721-A1 | ACRYLAMIDE COMPOUNDS | NRG Therapeutics LTD (GB) | 2025-01-08 | — | — | EP | disclosed |
| CN-118878545-A | Carbazolophenazinyl-containing compound, intermediate, organic electroluminescent device and display device | 阜阳欣奕华新材料科技股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| CN-118804911-A | Acrylamide compound | NRG治疗有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240067614-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD. (GB) | 2024-02-29 | — | — | US | disclosed |
| US-20240067614-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD. (GB) | 2024-02-29 | — | — | US | disclosed |
| CN-1284948-A | Indazole bioisostere replacement of catechol in therapeutically active compounds | PFIZER PROD INC (US) | 2001-02-21 | — | — | CN | disclosed |
| CN-1281441-A | Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors | PFIZER PROD INC (US) | 2001-01-24 | — | — | CN | disclosed |
| US-6127398-A | Substituted indazole derivatives and related compounds | PFIZER INC (US) | 2000-10-03 | — | — | US | disclosed |
| US-6040329-A | Substituted indazole analogs | PFIZER INC (US) | 2000-03-21 | — | — | US | disclosed |
| WO-2000012481-A2 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY________________ | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| CN-1234031-A | Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the prodn. of tumor necrosis factor (TNF) | PFIZER (US) | 1999-11-03 | — | — | CN | disclosed |
| US-5958953-A | Substituted indazole derivatives | PFIZER INC (US) | 1999-09-28 | — | — | US | disclosed |
| CN-1223651-A | Substituted indazole derivatives and their use as phosphodiesterase (PDE) type IV and tumor necrosis factor (TNF) inhibitors | PFIZER (US) | 1999-07-21 | — | — | CN | disclosed |
| CN-1217714-A | Substituted indazole derivatives and their use as Phosphodiesterase (PDE) type IV and inhibitors of the production of Tumor Necrosis Factor (TNF) | PFIZER (US) | 1999-05-26 | — | — | CN | disclosed |
| EP-0816357-A1 | Substituted indazole derivatives | PFIZER INC. (US) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630516-B2 | Compounds | CYP4B1, CYP1B1, NR4A1 | PDPK1 4130/4885JAK2 3513/4885GSK3B 2235/4885 |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PDPK1 30/4885JAK2 280/4885GSK3B 255/4885 |
| US-20240067614-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, CXCR2 | PDPK1 1983/4885JAK2 3124/4885GSK3B 1506/4885 |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | ACR, CCNI, FANCI | PDPK1 3904/4885JAK2 2138/4885GSK3B 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.